Galectin-3 Targeted Therapy with a Small Molecule Inhibitor Activates Apoptosis and Enhances Both Chemosensitivity and Radiosensitivity in Papillary Thyroid Cancer

Although most patients with papillary thyroid cancer (PTC) have favorable outcomes, some have advanced PTC that is refractory to external beam radiation and systemic chemotherapy. Galectin-3 (Gal-3) is a β-galactoside–binding protein with antiapoptotic activity that is consistently overexpressed in PTC. The purpose of this study is to determine if Gal-3 inhibition promotes apoptosis, chemosensitivity, and radiosensitivity in PTC. PTC cell lines (8505-C and TPC-1) and human ex vivo PTC were treated with a highly specific small molecule inhibitor of Gal-3 (Td131_1). Apoptotic activity was determined by flow cytometric analysis as well as caspase-3 and PARP cleavage. The minimum inhibitory concentrations of Td131_1 and doxorubicin were determined, and their combined effects were measured to test for synergistic activity. The effects of Td131_1 on radiosensitivity were determined by a clonogenic assay. Td131_1 promoted apoptosis, improved radiosensitivity, and synergistically enhanced chemosensitivity to doxorubicin in PTC cell lines. In PTC ex vivo, Td131_1 treatment alone induced the cleavage of caspase-3 and PARP. Td131_1 and doxorubicin together activated apoptosis in PTC ex vivo to a greater degree than their combined individual effects. Td131_1 activated apoptosis and had synergistic activity with doxorubicin in PTC. We conclude that Gal-3 targeted therapy is a promising therapeutic strategy for advanced PTC that is refractory to surgery and radioactive iodine therapy. (Mol Cancer Res 2009;7(10):1655–62)

[1]  M. Bertagnolli,et al.  Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. , 2009, Biochemical and biophysical research communications.

[2]  R. Kiss,et al.  Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. , 2008, Journal of medicinal chemistry.

[3]  S. Savin,et al.  Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. , 2008, Human pathology.

[4]  Weike Mao,et al.  ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. , 2008, American journal of physiology. Heart and circulatory physiology.

[5]  L. Moretti,et al.  Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer , 2008, Autophagy.

[6]  A. Bockisch,et al.  Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  A. Raben,et al.  The role of radiation therapy in the management of thyroid cancer. , 2008, Surgical oncology clinics of North America.

[8]  Joel Greshock,et al.  Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. , 2007, Cancer research.

[9]  S. Soddu,et al.  Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis , 2006, Molecular and Cellular Biology.

[10]  M. Bertagnolli,et al.  Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. , 2006, Cancer research.

[11]  R. Lotan,et al.  Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. , 2006, Cancer research.

[12]  Y. Takenaka,et al.  Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. , 2005, Cancer research.

[13]  Caitlin Smith.  Trouble in the hood: culturing difficult cell types , 2005, Nature Methods.

[14]  Nasreen S Jessani,et al.  Breast Cancer Cell Lines Grown In Vivo: What Goes in Isn’t Always the Same as What Comes Out , 2005, Cell cycle.

[15]  T. Yoshii,et al.  Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs , 2004, Molecular and Cellular Biology.

[16]  G. Jarvis,et al.  Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Shekhar,et al.  Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.

[18]  Q. Duh,et al.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.

[19]  C C Ling,et al.  Radiation-induced apoptosis: relevance to radiotherapy. , 1995, International journal of radiation oncology, biology, physics.